The controversial inflationary rebate policy in the Senate Finance Committee’s drug-pricing package could incentivize drug makers to raise prices before the bill would take effect in 2022, sources say. Others disagree and say that drug makers could make up revenue in different ways. The inflationary rebates as outlined in the plan passed by the Finance Committee would begin in 2022 and would be indexed to July 2019 list prices trended forward by inflation. Starting Jan. 1, 2022, drug makers would...